RPL7P9

Across TCGA pan-cancer cohorts, RPL7P9 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RPL7P9’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL7P9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL7P9 is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

KIRC, LIHC, and CHOL are the cancer types where RPL7P9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL7P9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.617	<.001	10	view →
LIHC	All	II,III,IV	+1.336	<.001	7	view →
CHOL	Male	All	+2.420	<.001	5	view →
LUSC	All	All	+0.413	.001	5	view →
BRCA	All	All	−0.248	.025	4	view →
STAD	All	II,III,IV	+0.587	.024	2	view →
KICH	Female	All	−0.557	.021	2	view →
KIRP	All	III,IV	+0.394	.041	2	view →
BLCA	Male	IV	−0.792	.047	1	view →
THCA	Female	II,III,IV	+0.572	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RPL7P9–KIRC

Open the KIRC breakdown →